

Oncology Today with Dr Neil Love: Advances in the Treatment of Hodgkin and Non-Hodgkin Lymphomas from ASH 2021**THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.**

- 1. Which of the following trials reported at ASH 2021 that CAR (chimeric antigen receptor) T-cell therapy significantly improved event-free survival in patients with lymphoma?**
 - ZUMA-7 only
 - TRANSFORM only
 - BELINDA only
 - ZUMA-7 and BELINDA only
 - TRANSFORM and ZUMA-7 only**
 - BELINDA, ZUMA-7 and TRANSFORM
- 2. At ASH 2021, which of the following results was reported from the Phase II UNITY-NHL trial combining ublituximab and umbralisib in patients with previously untreated marginal zone lymphoma?**
 - Increased complete response rate with combination therapy compared to umbralisib monotherapy**
 - All-grade diarrhea affected 67% of the patients and grade 3/4 diarrhea affected 24%
 - Median progression-free survival was 14.21 months at a median follow-up of 20 months
- 3. Which of the following best describes the mechanism of action of the novel drug mosunetuzumab?**
 - Checkpoint inhibitor
 - PI3K inhibitor
 - Bispecific T-cell engaging therapy**
- 4. Based on the retrospective analysis presented at ASH 2021 of real-world experience (RWE) with brexucabtagene autoleucel (brexu-cel) in 107 patients with relapsed/refractory mantle cell lymphoma and data from the ZUMA-2 trial that led to the approval of brexu-cel, which of the following is true?**
 - The rate of 12-month progression-free survival was 25% less in RWE than in ZUMA-2
 - The complete response rate was not significantly different in RWE and ZUMA-2**
 - The incidence of grade 3 immune effector cell-associate neurotoxicity syndrome was lower in the RWE than in ZUMA-2
 - The incidence of grade 3 cytokine release syndrome was higher in RWE than in ZUMA-2
 - All of the above